TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00663286
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application for 12 weeks
Study: NCT01356732
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
Study: NCT00527020
Drug: GSK1018921
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
Study: NCT00527020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be given to the subjects.
Study: NCT00167180
Drug: Induction Chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
Study: NCT04149860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for solution for IV infusion
Study: NCT03935555
Drug: PU-H71
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
Study: NCT04311658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
Study: NCT02532712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with same shape and size
Study: NCT01862835
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02699151
Drug: any drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
Study: NCT03333395
Drug: Nebulized heparin and salbutamol
Normalized name: salbutamol and budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
Study: NCT03968159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2×placebo tablets \[size- and color-matched to pimavanserin\]) administered orally as a single dose once daily
Study: NCT00667654
Drug: CNTX-4975
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testing a range of dosing configurations to optimize patient tolerability
Study: NCT03577392
Drug: oxaliplatin + capecitabine (XELOX chemotherapy)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
Study: NCT00846989
Drug: RKI983A
Approvals — FDA: no, EMA: no, PMDA: no
Description: RKI983 0.05 % twice daily
Study: NCT00846989
Drug: RKI983A
Approvals — FDA: no, EMA: no, PMDA: no
Description: RKI983 0.1 % twice daily
Study: NCT01390324
Drug: Fixed-dose combination of naratriptan+naproxen
Normalized name: combinations of barbiturates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing naratriptan 2,5 mg + naproxen 500 mg
Study: NCT01390324
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets containing naproxen 500 mg
Study: NCT00002824
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00136825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01724424
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg oral single dose
Study: NCT01724424
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mg oral single dose
Study: NCT01724424
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg oral single dose
Study: NCT01724424
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg oral single dose
Study: NCT04035096
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~2. The final dose will be kept for 12 weeks.~3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks
Study: NCT00206284
Drug: AZD0865
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00432744
Drug: CoenzymeQ10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
Study: NCT00432744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
Study: NCT03844113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
Study: NCT00005013
Drug: Hypericum perforatum (St. John's wort)
Normalized name: HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00468845
Drug: matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT03216486
Drug: BPS804
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of BPS804 in 5% Dextrose solution
Study: NCT01228994
Drug: placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill
Study: NCT03553498
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen given intravenously
Study: NCT03553498
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: given intravenously
Study: NCT04272008
Drug: Segesterone Acetate and Ethinyl Estradiol
Normalized name: ETHINYL ESTRADIOL/SEGESTERONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annovera taken alone
Study: NCT01887119
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04867941
Drug: ACP-196
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
Study: NCT03596073
Drug: Topical Calcipotriene Ointment
Normalized name: calcipotriene Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
Study: NCT01708447
Drug: L.M.X.4.® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: A lidocaine topical anesthetic cream
Study: NCT02333149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo frequency and volume are identical to the experimental arm
Study: NCT00030771
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
Study: NCT01442792
Drug: UFH
Normalized name: Ibrufhalal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
Study: NCT02581462
Drug: FLOT alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-operative therapy:~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43
Study: NCT00906451
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin
Study: NCT03132519
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
Study: NCT00549185
Drug: SAR3419
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04102553
Drug: F-18-PSMA-1007
Normalized name: PSMA-1007 (18F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Study: NCT04102553
Drug: F-18-Fluorocholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Study: NCT00098722
Drug: optimized background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[OBT (3-6 drugs based on treatment history and resistance testing)\]
Study: NCT00552630
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with same characteristics as drug
Study: NCT00934947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill
Study: NCT03384823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match EDP-938
Study: NCT02898961
Drug: 30 mg/kg amikacin or 8 mg/kg gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion.
Study: NCT00736775
Drug: anti-Abeta
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single and multiple doses
Study: NCT00736775
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single and multiple doses
Study: NCT03518268
Drug: Vivomixx
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
Study: NCT03518268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention consists of 2 sachets a day of placebo, for 6 months
Study: NCT01974752
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
Study: NCT00596245
Drug: MT400
Normalized name: Sumatriptan/naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT 400, naproxen sodium 550mg
Study: NCT03554772
Drug: DFN-15 (Celecoxib Oral Solution) 62.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT03554772
Drug: DFN-15 (Celecoxib Oral Solution) 125 mg
Normalized name: celecoxib Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT03554772
Drug: DFN-15 (Celecoxib Oral Solution) 250 mg
Normalized name: celecoxib Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT03554772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT03859739
Drug: MK-8558
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
Study: NCT02061397
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
Study: NCT00506155
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m\^2 by vein over 15 minutes
Study: NCT00506155
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mg/m\^2 by vein over 30 minutes
Study: NCT00203112
Drug: glatiramer acetate with minocycline
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
Study: NCT04355858
Drug: SHR7390
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK1/2 inhibitor
Study: NCT04355858
Drug: SHR3162
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitor
Study: NCT04355858
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.
Study: NCT04355858
Drug: SHR1210
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody
Study: NCT04355858
Drug: SHR2554
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZH2 inhibitor
Study: NCT04355858
Drug: SHR3680
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR inhibitor
Study: NCT04355858
Drug: SHR1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-L1/TGF-βRII bifunctional fusion protein
Study: NCT03062618
Drug: PRCL-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet(s) administered with water
Study: NCT03062618
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered with water
Study: NCT01355263
Drug: iron and vitamin a
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00188851
Drug: therapeutic management strategy
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01414205
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were administered corticosteroids IV prior to the initial dose.
Study: NCT03523273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration will match the study drug.
Study: NCT00273754
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
Study: NCT00273754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children in group two will receive an amount of normal saline equal to Caffeine
Study: NCT03081676
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03081676
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline)
Study: NCT00642148
Drug: GW856553
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tablet
Study: NCT00642148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet and inhaler
Study: NCT01657136
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different drugs
Study: NCT00645879
Drug: ornithine alpha ketoglutarate
Normalized name: ornithine alpha-ketoglutarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
Study: NCT00885638
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo tablet is given before ingestion of macronutrients
Study: NCT02262819
Drug: S. aureus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
Study: NCT04304794
Drug: Prophylactic administration of antithyroid drugs before iodinated contrast media exposure
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
Study: NCT03745144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
Study: NCT02120365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given in place of perampanel during the pre-treatment period and lab session days.
Study: NCT01063842
Drug: tramadol hydrochloride /acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
Study: NCT01063842
Drug: tramadol hydrochloride / acetaminophen and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
Study: NCT03785587
Drug: Sofpironium Bromide Gel, 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofpironium Bromide Gel, 15%
Study: NCT02844283
Drug: Ad-HGF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02047201
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
Study: NCT00882908
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
Study: NCT00882908
Drug: PegIFNα-2a (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
Study: NCT00882908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
Study: NCT00700102
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT02525939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets
Study: NCT00196859
Drug: Ibandronate, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
Study: NCT00196859
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
Study: NCT03745144
Drug: Microgynon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Microgynon® tablet once daily for 21 days in treatment period 1 and 2. Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle in Run-in period.
Study: NCT04278937
Drug: Azithromycin Tablets
Normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks
Study: NCT01826266
Drug: PER977, Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01582048
Drug: immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
Study: NCT00160199
Drug: PROMETRIUM® 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
Study: NCT00160199
Drug: PROMETRIUM® 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
Study: NCT02182674
Drug: Placebo Combivent HFA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182674
Drug: Combivent HFA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182674
Drug: Placebo Combivent (CFC)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02452853
Drug: FOLFOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks
Study: NCT00302016
Drug: AMN107
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01592019
Drug: Reference, Patch location thigh, batch 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference, Patch location thigh, batch 1
Study: NCT01592019
Drug: Reference, Patch location abdomen, batch 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference, Patch location abdomen, batch 1
Study: NCT01853072
Drug: Nepafenac Ophthalmic Suspension, 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test intervention
Study: NCT01853072
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks